U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06893380) titled 'Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer (GemCiNT)' on March 12.
Brief Summary: This is a multicenter Phase 1b/2 clinical trial investigating the efficacy and safety of a combination regimen of Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab in treatment-naive patients with unresectable, locally advanced, or metastatic biliary tract cancers (BTC), including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.
The Phase 1b portion aims to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Nab-paclitaxel in combination w...